iC1e/K: meta-analysis of COVID-19 studies

All studies   Mortality   Serious outcomes   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 20 patientsc19early.org

iC1e/K for COVID-19

Serious outcome risk
iC1e/K
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)0%
Mortality (1)0%
RCTs (1)0%
Late (1)0%
00.511.5+
← iC1e/K
reduces riskIncreased
risk →
c19early.org
October 2026

IC1e/K COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Mansour (RCT)0%1.00 · 0.07–13.87death1/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← iC1e/K
reduces riskiC1e/K
increases risk →
c19early.org
October 2026

IC1e/K COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Mansour (RCT)0%1.00 · 0.07–13.871/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← iC1e/K
reduces riskiC1e/K
increases risk →
c19early.org
October 2026

IC1e/K COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Mansour (RCT)0%1.00 · 0.07–13.87death1/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← iC1e/K
reduces riskiC1e/K
increases risk →
c19early.org
October 2026

IC1e/K COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Mansour (RCT)−35%1.35 · 0.72–2.55no disch.10 (n)10 (n)
Late treatment−35%1.35 · 0.72–2.5510 (n)10 (n)35% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.36
All studies−35%1.35 · 0.72–2.5510 (n)10 (n)35% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.3600.511.52+
Rotate screen for more detailsIncrease width for more details
← iC1e/K
reduces riskiC1e/K
increases risk →
c19early.org
October 2026

IC1e/K COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Mansour (RCT)0%1.00 · 0.07–13.87death1/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← iC1e/K
reduces riskiC1e/K
increases risk →
c19early.org
October 2026

IC1e/K COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Mansour (RCT)0%1.00 · 0.07–13.871/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← iC1e/K
reduces riskiC1e/K
increases risk →
c19early.org
October 2026

IC1e/K COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Mansour (RCT)0%1.00 · 0.07–13.87death1/101/10
Late treatment0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.07–13.871/101/100% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← iC1e/K
reduces riskiC1e/K
increases risk →